Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EDOCAL

Financiado

Cerrado

Early Detection Of CAncer using photonic crystal Lasers

In Europe there are 3 million new cancer cases per year. According to the WHO the burden of cancer can be reduced by systematic and equitable implementation of evidence based strategies for cancer prevention, early detection and m... ver más

31/12/2011

ROBSONS INTERNATIO...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

ROBSON MICHAEL ALAN No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-12-31 No tenemos la información de la convocatoria

0% 80% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

ROBSONS INTERNATIONAL RAIL C...

0.00€ | Lider

Tayside Health Board

N.D. | Participante

CSTG

N.D. | Participante

Proyectos interesantes

LOUISA 3D

Medical Technol...

Applied Physics

71K€ Cerrado

BIO2008-06843-C04-01

Medical Technol...

Applied Physics

121K€ Cerrado

CLI

Medical Technol...

Applied Physics

2M€ Cerrado

LASER-HISTO

Medical Technol...

Applied Physics

2M€ Cerrado

SOLUS

Medical Technol...

Applied Physics

4M€ Cerrado

PHAST

Medical Technol...

Applied Physics

4M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ROBSON MICHAEL ALAN No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In Europe there are 3 million new cancer cases per year. According to the WHO the burden of cancer can be reduced by systematic and equitable implementation of evidence based strategies for cancer prevention, early detection and management of patients with cancer. 33% of the cancer burden could be reduced if detected early and treated adequately. The WHO concludes that, early diagnosis of cancers could save the developed world an average of €40 billion per year on medical costs and €80 billion per year on realized productivity. The direct savings on medical treatment alone would be more than €10.000 per patient if early detection was possible. Early cancer diagnosis today consists of recognition of some of the ‘early’ signs by the patient themselves or detection from screenings carried out on specific population groups. If something suspicious is found the next step is to perform a blood analysis and/or to look with non-invasive imaging techniques. Current imaging techniques are widely used in diagnostic procedures but they cannot give conclusive evidence of cancer. Today, only a biopsy and the subsequent pathologist’s interpretation can give a definitive diagnosis of cancer and this is not always enough EDOCAL will use a tunable blue laser to selectively excite an accumulated photo sensitizer, called proto-porphyrin. This sensitizer is taken by the patient to enhance contrast between healthy and cancerous tissue. Reflected light is filtered using state of the art ultra narrow photonic crystal technology. Initial studies have shown that it is possible to detect cancerous tissue using blue light in combination with FDA approved sensitizers (ALA-5 and Proto-Porphyrin). This tool will be based on the principle of preferential retention of proto-porphyrin by cancer cells. The purpose of this project is to create a breakthrough tool for early cancer detection by combining state of the art laser and imaging technology with leading medical research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores